Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Public ClinicalTrials.gov record NCT03393000. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Open-label, randomized, controlled, phase 3 safety and efficacy registration trial. Subjects will be randomized at baseline to the standard of care for first-line treatment of glioblastoma plus Trans Sodium Crocetinate (TSC) or the standard of care. The standard of care for GBM will consist of temozolomide plus radiation therapy for 6 weeks followed by 28 days of rest followed by 6 cycles of post-radiation temozolomide treatment.
Study identification
- NCT ID
- NCT03393000
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 16, 2018 (Actual)
- Primary completion
- Nov 6, 2020 (Actual)
- Completion
- Nov 6, 2020 (Actual)
- Last update posted
- Jul 22, 2021
2018 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California | Irvine | California | 92868 | — |
| Scott Peak, M.D. | Redwood City | California | 94063 | — |
| John Wayne Cancer Institute @ Providence Saint John's Health Center | Santa Monica | California | 90404 | — |
| Piedmont Cancer | Atlanta | Georgia | 30318 | — |
| John B. Amos Cancer Center | Columbus | Georgia | 31904 | — |
| Abbott Northwestern Hospital | Minneapolis | Minnesota | 55407 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| UNM Comprehensive Cancer Center | Albuquerque | New Mexico | 87102 | — |
| North Shore University Hospital | Manhasset | New York | 11030 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Scott Lindhorst, M.D. | Charleston | South Carolina | 29425 | — |
| Neuro Oncology Associates | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03393000, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03393000 live on ClinicalTrials.gov.